Abstract
A highly sensitive and simple spectrofluorimetric method has been developed and validated for the determination of dasatinib (DSB) in its pharmaceutical formulations, spiked human plasma and urine. The suggested method depended on studying the fluorescence spectral behavior of DSB in Cremophor EL (Cr EL) micellar system using synchronous scan technique (Delta lambda = 50 nm). In aqueous solution, the fluorescence intensity of DSB was markedly enhanced in the presence of Cr EL. The fluorescence-concentration plot was rectilinear over the range 25-500 ng mL(-1), with lower detection limit of 2.70 ng mL(-1). The proposed method was successfully applied to the assay of commercial tablets, spiked human plasma and urine samples as well as content uniformity test. The application of the proposed method was extended to test the in vitro drug release of DSB tablets, according to United States Pharmacopeia (USP) guidelines.